News

In both laboratory and animal testing, CUDC-305 demonstrated high potency in vitro and in vivo across a wide range of cancers. Tumor regression has also been observed after

The primary endpoint of the study is objective response rate (complete and partial response). Secondary endpoints include duration of response, clinical benefit rate, progression-free survival (PFS), overall survival

James Whittenburg, CEO of HealthTronics, said: “HealthTronics brings deep and capable resources to bear in restructuring the existing UroPath model to fully address the regulatory environment while preserving,

Mr Eagle most recently served as director of eCommerce systems and director of retail systems at Ann Arbor, Michigan-based Borders Group, a retailer of books, music and movies.

The new non-exclusive, gene-specific license agreement includes an Alnylam right of first negotiation to opt-in for co-development and co-commercialization of the RNAi therapeutic product in the US market.

The addition of AccuNurse to TeleHealth’s family of interactive solutions is said to enable TeleHealth customers to leverage voice-assisted care as part of the overall solution, with the

ApoB Snalp will enter a Phase I human clinical trial in the first half of 2009 as a treatment for high cholesterol. In preclinical studies, ApoB Snalp was

Cenix will apply its expertise in combining high throughput applications of small RNA-based gene silencing with high content phenotypic analyses in cultured human cells. The company will thereby

The company has cancelled 1.98 million of two million outstanding shares of Pawfect common stock surrendered by a principal stockholder as a condition of the exchange and financing,